NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|1952201268|ref|WP_199529678|]
View 

aminopeptidase N [Pseudoalteromonas sp. bablab_jr010]

Protein Classification

M1 family metallopeptidase( domain architecture ID 11487037)

M1 family metallopeptidase is a zinc-dependent metallopeptidase that functions as an aminopeptidase and contains an HEXXH motif as part of its active site; such as aminopeptidase N, which is a type II integral membrane protease that preferentially cleaves neutral amino acids from the N-terminus of oligopeptides

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
4-864 0e+00

aminopeptidase N; Provisional


:

Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1486.15  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268   4 TSKPQAQYLKDYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAY--DDYTLE 79
Cdd:PRK14015    3 TQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVrrNPDAAHSAPLVLDGEDLELLSLALDGQPLapSAYELD 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  80 DEKLIIHNLPESFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLS 158
Cdd:PRK14015   83 EEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKaKYPVLLS 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 159 NGNQIESGNLDDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWD 238
Cdd:PRK14015  163 NGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKWD 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 239 EERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLS 318
Cdd:PRK14015  243 EERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLS 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 319 LKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGE 398
Cdd:PRK14015  323 LKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLGE 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 399 EKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYSQAGTPKLNVEQAYDEQNQTFTLSIEQFAPD--NQPN 476
Cdd:PRK14015  403 EGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPtpGQPE 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 477 NALLHIPFAIELLDSEGQSLPLVIDNQPQDSVLNVTEKTQQFVFEGIKQRPVAVLLEDFSAPCIVNQNTSAADLLHIMRF 556
Cdd:PRK14015  483 KQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMAH 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 557 ARSDFSRWDAQQRLFTNEMKAAIAS-GEAC-LSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAAEYAVIPVDDIIA 634
Cdd:PRK14015  563 DSDPFNRWEAGQRLATRLLLANVARhGQPLsLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDAIHA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 635 VQNAFESQIANFLTESLVNCYNVLEDDGSTSATAVAV--RALKQLCLYYLAKTNHSDVNSRIRE-SVHSNNMTNALAALS 711
Cdd:PRK14015  643 AREALRRALATALKDELLALYEALQTDGPYSPDAEAAgrRALRNVCLSYLAAADDEEAAELAEAqFDQADNMTDRLAALS 722
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 712 AVVKANHSLCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALVGSFSHFNITQFH 791
Cdd:PRK14015  723 ALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANPAGFH 802
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 792 RADGEGYQLLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVEKALES 864
Cdd:PRK14015  803 AADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
4-864 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1486.15  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268   4 TSKPQAQYLKDYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAY--DDYTLE 79
Cdd:PRK14015    3 TQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVrrNPDAAHSAPLVLDGEDLELLSLALDGQPLapSAYELD 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  80 DEKLIIHNLPESFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLS 158
Cdd:PRK14015   83 EEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKaKYPVLLS 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 159 NGNQIESGNLDDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWD 238
Cdd:PRK14015  163 NGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKWD 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 239 EERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLS 318
Cdd:PRK14015  243 EERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLS 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 319 LKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGE 398
Cdd:PRK14015  323 LKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLGE 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 399 EKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYSQAGTPKLNVEQAYDEQNQTFTLSIEQFAPD--NQPN 476
Cdd:PRK14015  403 EGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPtpGQPE 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 477 NALLHIPFAIELLDSEGQSLPLVIDNQPQDSVLNVTEKTQQFVFEGIKQRPVAVLLEDFSAPCIVNQNTSAADLLHIMRF 556
Cdd:PRK14015  483 KQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMAH 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 557 ARSDFSRWDAQQRLFTNEMKAAIAS-GEAC-LSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAAEYAVIPVDDIIA 634
Cdd:PRK14015  563 DSDPFNRWEAGQRLATRLLLANVARhGQPLsLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDAIHA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 635 VQNAFESQIANFLTESLVNCYNVLEDDGSTSATAVAV--RALKQLCLYYLAKTNHSDVNSRIRE-SVHSNNMTNALAALS 711
Cdd:PRK14015  643 AREALRRALATALKDELLALYEALQTDGPYSPDAEAAgrRALRNVCLSYLAAADDEEAAELAEAqFDQADNMTDRLAALS 722
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 712 AVVKANHSLCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALVGSFSHFNITQFH 791
Cdd:PRK14015  723 ALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANPAGFH 802
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 792 RADGEGYQLLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVEKALES 864
Cdd:PRK14015  803 AADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
14-862 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1202.53  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  14 DYQAPQFSIKHIDLRFELAPLKTSVQSTMTINRTDESNAD-LLLDGVDLTLISLMVDDK--AYDDYTLEDEKLIIHNLPE 90
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPDGNGApLVLDGEELKLLSIAIDGKplAAGDYQLDDETLTIASVPE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  91 SFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLSNGNQIESGNLD 169
Cdd:TIGR02414  81 SFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKkKYPVLLSNGNKIASGELP 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 170 DGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFNLEYDLD 249
Cdd:TIGR02414 161 DGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDLD 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 250 IYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 329
Cdd:TIGR02414 241 IFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 330 EFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMALYF 409
Cdd:TIGR02414 321 EFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLYF 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 410 ERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYSQAGTPKLNVEQAYDEQNQTFTLSIEQFAP--DNQPNNALLHIPFAIE 487
Cdd:TIGR02414 401 SRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPptPGQTEKKPLHIPIAVG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 488 LLDSEGQSLPLVIDNQPQDS-VLNVTEKTQQFVFEGIKQRPVAVLLEDFSAPCIVNQNTSAADLLHIMRFARSDFSRWDA 566
Cdd:TIGR02414 481 LLGPNGRKLMLSLDGERDTTrVLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPFNRWEA 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 567 QQRLFTNEMKAAIAS---GEAC-LSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAAEYAVIPVDDIIAVQNAFESQ 642
Cdd:TIGR02414 561 GQRLARRVILANIARaqgGEELpVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAAREFLRAA 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 643 IANFLTESLVNCYNVLEDDGSTSATAVAV--RALKQLCLYYLAKTNHSDVNSRI-RESVHSNNMTNALAALSAVVKANHS 719
Cdd:TIGR02414 641 IARQLADDLLRLYDALQENGPYSVDPAAAgrRALRNACLSYLSAADDAEIRNLAlEQFKSADNMTDRLAALSALVHFESD 720
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 720 LCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALVGSFSHFNITQFHRADGEGYQ 799
Cdd:TIGR02414 721 FRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRFHDISGSGYR 800
                         810       820       830       840       850       860
                  ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 800 LLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVEKAL 862
Cdd:TIGR02414 801 FLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
14-442 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 851.81  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  14 DYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAY--DDYTLEDEKLIIHNLP 89
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVrrNPDSGEGAPLVLDGEDLELLSVKIDGKPLspSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  90 ESFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLSNGNQIESGNL 168
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKeKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 169 DDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFNLEYDL 248
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 249 DIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 328
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 329 QEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMALY 408
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 1952201268 409 FERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYS 442
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
7-622 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 566.58  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268   7 PQAQYLKDYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAYDdYTLEDEKLI 84
Cdd:COG0308     2 KRLTRLEAYRPPGYDVTHYDLDLDLDPATTRLSGTATItfTATEAPLDSLVLDLKGLEVTSVTVDGKPLD-FTRDGERLT 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  85 IH---NLP--ESFILKIENHIVPQTntSLEGLYLSG------GAYCTQCEAEGFRkiTYYL--DRPDVLASFDVTIIADK 151
Cdd:COG0308    81 ITlpkPLApgETFTLEIEYSGKPSN--GGEGLYRSGdppdgpPYLYTQCEPEGAR--RWFPcfDHPDDKATFTLTVTVPA 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 152 KYThLLSNGNQIESGNLDDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYttQSGrkVELALFVDKGNLSKTPHAMTSL 231
Cdd:COG0308   157 GWV-AVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAFEST 231
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 232 KKSMQWDEERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVlaNQETATDKDYHTIESIVGHEYFHNWTGNRVTC 311
Cdd:COG0308   232 KRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVL--ADETATDADYERRESVIAHELAHQWFGNLVTC 309
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 312 RDWFQLSLKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRM 391
Cdd:COG0308   310 ADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHM 389
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 392 MHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLT-QFKRWYSQAGTPKLNVEQAYDEQNQTfTLSIEQFA 470
Cdd:COG0308   390 LRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSaFFDQWLYQAGLPTLEVEYEYDADGKV-TLTLRQTP 468
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 471 PDNQPnnalLHIPFAIELLDSEGQSLPLVIDnqpqdsvlnvTEKTQqfvfegIKQRPVAVLLEDFSapcivnqntsaADL 550
Cdd:COG0308   469 PRPHP----FHIPLEVGLLGGKLTARTVLLD----------GEQTE------LVAKPDPVLLLRLD-----------DEL 517
                         570       580       590       600       610       620       630
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 1952201268 551 LHIMRFARSDFSRWDAQQRLFtnemkaaiASGEAclsddilSALKLLVDNREGDLALIAELLKLPSYDTLAA 622
Cdd:COG0308   518 AFLLAHDSDPFNRWEALQALW--------RDGEA-------DYLDALRALADTDPAVRAEALALLGSDQLAL 574
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
547-863 3.62e-122

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 371.85  E-value: 3.62e-122
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 547 AADLLHIMRFARSDFSRWDAQQRLFTNEMKAAIA----SGEACLSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAA 622
Cdd:pfam17432   1 DEDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAalqaGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 623 EYAVIPVDDIIAVQNAFESQIANFLTESLVNCYNVLEDDG--STSATAVAVRALKQLCLYYLAKTNHSDVNSRIRESVHS 700
Cdd:pfam17432  81 QMDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGpySPDAAAAGRRALRNLALSYLAAAGDPEAADLAAAQFES 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 701 -NNMTNALAALSAVVKANHSLCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALV 779
Cdd:pfam17432 161 aDNMTDRLAALAALVNSDLPEREEALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVRALI 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 780 GSFSHFNITQFHRADGEGYQLLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVE 859
Cdd:pfam17432 241 GAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFEIVS 320

                  ....
gi 1952201268 860 KALE 863
Cdd:pfam17432 321 KALA 324
 
Name Accession Description Interval E-value
pepN PRK14015
aminopeptidase N; Provisional
4-864 0e+00

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 1486.15  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268   4 TSKPQAQYLKDYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAY--DDYTLE 79
Cdd:PRK14015    3 TQQPQAIYLKDYRPPDYLIDTVDLDFDLDPDKTRVTARLQVrrNPDAAHSAPLVLDGEDLELLSLALDGQPLapSAYELD 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  80 DEKLIIHNLPESFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLS 158
Cdd:PRK14015   83 EEGLTIENLPDRFTLEIETEIDPEANTALEGLYRSGGMFCTQCEAEGFRRITYFLDRPDVLARYTVRIEADKaKYPVLLS 162
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 159 NGNQIESGNLDDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWD 238
Cdd:PRK14015  163 NGNLVESGELPDGRHWATWEDPFPKPSYLFALVAGDLDVLEDTFTTRSGREVALEIYVEPGNLDKCDHAMDSLKKSMKWD 242
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 239 EERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLS 318
Cdd:PRK14015  243 EERFGLEYDLDIFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLS 322
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 319 LKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGE 398
Cdd:PRK14015  323 LKEGLTVFRDQEFSADLGSRAVKRIEDVRVLRAAQFAEDAGPMAHPVRPDSYIEINNFYTATVYEKGAEVIRMLHTLLGE 402
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 399 EKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYSQAGTPKLNVEQAYDEQNQTFTLSIEQFAPD--NQPN 476
Cdd:PRK14015  403 EGFRKGMDLYFERHDGQAVTCEDFVAAMEDASGRDLSQFRRWYSQAGTPRVTVSDEYDAAAGTYTLTLSQSTPPtpGQPE 482
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 477 NALLHIPFAIELLDSEGQSLPLVIDNQPQDSVLNVTEKTQQFVFEGIKQRPVAVLLEDFSAPCIVNQNTSAADLLHIMRF 556
Cdd:PRK14015  483 KQPLHIPVAIGLLDPDGKELPLQLEGEPVERVLELTEAEQTFTFENVAERPVPSLLRGFSAPVKLEYDYSDEDLLFLMAH 562
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 557 ARSDFSRWDAQQRLFTNEMKAAIAS-GEAC-LSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAAEYAVIPVDDIIA 634
Cdd:PRK14015  563 DSDPFNRWEAGQRLATRLLLANVARhGQPLsLDEALIDAFRAVLLDESLDPAFAAELLTLPSEAELAEQMEVIDPDAIHA 642
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 635 VQNAFESQIANFLTESLVNCYNVLEDDGSTSATAVAV--RALKQLCLYYLAKTNHSDVNSRIRE-SVHSNNMTNALAALS 711
Cdd:PRK14015  643 AREALRRALATALKDELLALYEALQTDGPYSPDAEAAgrRALRNVCLSYLAAADDEEAAELAEAqFDQADNMTDRLAALS 722
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 712 AVVKANHSLCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALVGSFSHFNITQFH 791
Cdd:PRK14015  723 ALVNADLPERDEALADFYDRWKDDPLVMDKWFALQATSPAPDTLERVRALMQHPAFDLKNPNRVRSLIGAFAAANPAGFH 802
                         810       820       830       840       850       860       870
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 792 RADGEGYQLLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVEKALES 864
Cdd:PRK14015  803 AADGSGYRFLADQILALDKINPQVAARLATPLIRWRRYDPKRQALMRAALERIAALPNLSKDVREIVSKALAA 875
pepN_proteo TIGR02414
aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a ...
14-862 0e+00

aminopeptidase N, Escherichia coli type; The M1 family of zinc metallopeptidases contains a number of distinct, well-separated clades of proteins with aminopeptidase activity. Several are designated aminopeptidase N, EC 3.4.11.2, after the Escherichia coli enzyme, suggesting a similar activity profile (see SP|P04825 for a description of catalytic activity). This family consists of all aminopeptidases closely related to E. coli PepN and presumed to have similar (not identical) function. Nearly all are found in Proteobacteria, but members are found also in Cyanobacteria, plants, and apicomplexan parasites. This family differs greatly in sequence from the family of aminopeptidases typified by Streptomyces lividans PepN (TIGR02412), from the membrane bound aminopeptidase N family in animals, etc. [Protein fate, Degradation of proteins, peptides, and glycopeptides]


Pssm-ID: 274122 [Multi-domain]  Cd Length: 863  Bit Score: 1202.53  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  14 DYQAPQFSIKHIDLRFELAPLKTSVQSTMTINRTDESNAD-LLLDGVDLTLISLMVDDK--AYDDYTLEDEKLIIHNLPE 90
Cdd:TIGR02414   1 DYKPPPFLIEKTHLDFDLHEEETVVRARLTVRRNPDGNGApLVLDGEELKLLSIAIDGKplAAGDYQLDDETLTIASVPE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  91 SFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLSNGNQIESGNLD 169
Cdd:TIGR02414  81 SFTLEIETEIHPEENTSLEGLYKSGGNFCTQCEAEGFRRITYFPDRPDVMSRYTVTITADKkKYPVLLSNGNKIASGELP 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 170 DGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFNLEYDLD 249
Cdd:TIGR02414 161 DGRHWAEWEDPFPKPSYLFALVAGDLDVLEDTFTTKSGREVALRVYVEEGNKDKCDHAMESLKKAMKWDEEVFGLEYDLD 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 250 IYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 329
Cdd:TIGR02414 241 IFMIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQ 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 330 EFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMALYF 409
Cdd:TIGR02414 321 EFSADMTSRAVKRIEDVRLLRAHQFPEDAGPMAHPVRPESYVEINNFYTATVYEKGAEVIRMLHTLLGEEGFRKGMDLYF 400
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 410 ERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYSQAGTPKLNVEQAYDEQNQTFTLSIEQFAP--DNQPNNALLHIPFAIE 487
Cdd:TIGR02414 401 SRHDGQAVTCEDFVAAMEDASGRDLNQFRRWYSQAGTPVLEVKENYDAAKKTYTLTVRQSTPptPGQTEKKPLHIPIAVG 480
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 488 LLDSEGQSLPLVIDNQPQDS-VLNVTEKTQQFVFEGIKQRPVAVLLEDFSAPCIVNQNTSAADLLHIMRFARSDFSRWDA 566
Cdd:TIGR02414 481 LLGPNGRKLMLSLDGERDTTrVLELTEAEQTFVFEGIAEKPVPSLLRGFSAPVNLEYPYSDEDLLLLLAHDSDPFNRWEA 560
                         570       580       590       600       610       620       630       640
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 567 QQRLFTNEMKAAIAS---GEAC-LSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAAEYAVIPVDDIIAVQNAFESQ 642
Cdd:TIGR02414 561 GQRLARRVILANIARaqgGEELpVDPAFIDALGKLLNDPHLDAAFKALLLALPSEAYLAELMENIDPDALHAAREFLRAA 640
                         650       660       670       680       690       700       710       720
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 643 IANFLTESLVNCYNVLEDDGSTSATAVAV--RALKQLCLYYLAKTNHSDVNSRI-RESVHSNNMTNALAALSAVVKANHS 719
Cdd:TIGR02414 641 IARQLADDLLRLYDALQENGPYSVDPAAAgrRALRNACLSYLSAADDAEIRNLAlEQFKSADNMTDRLAALSALVHFESD 720
                         730       740       750       760       770       780       790       800
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 720 LCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALVGSFSHFNITQFHRADGEGYQ 799
Cdd:TIGR02414 721 FRERALAAFYQKWKDDPLVMDKWFALQATSPRPDTLERVKALLQHPAFDLKNPNRVRALIGAFANNNLVRFHDISGSGYR 800
                         810       820       830       840       850       860
                  ....*....|....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 800 LLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVEKAL 862
Cdd:TIGR02414 801 FLADQIIAIDRFNPQVAARLLEPLTRWRKLDPKRQELMKAALERIAAEENLSKDVREVVSKAL 863
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
14-442 0e+00

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 851.81  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  14 DYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAY--DDYTLEDEKLIIHNLP 89
Cdd:cd09600     1 DYKPPDFLIDHVDLDFDLDDDETIVTSRLRVrrNPDSGEGAPLVLDGEDLELLSVKIDGKPLspSDYTLDEEGLTIKNVP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  90 ESFILKIENHIVPQTNTSLEGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADK-KYTHLLSNGNQIESGNL 168
Cdd:cd09600    81 DRFVLEIEVRINPAANTSLEGLYKSGGILCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADKeKYPVLLSNGNLIEEGEL 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 169 DDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFNLEYDL 248
Cdd:cd09600   161 PNGRHFAVWEDPFPKPSYLFALVAGDLGSVEDTFTTKSGRKVKLRIYVEPGNEDKCHHAMESLKKAMKWDEERFGLEYDL 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 249 DIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 328
Cdd:cd09600   241 DLFNIVAVDDFNMGAMENKGLNIFNSKYVLADPETATDADYERIESVIAHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRD 320
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 329 QEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMALY 408
Cdd:cd09600   321 QEFSADMNSRAVKRIEDVRRLRSAQFPEDAGPMAHPIRPDSYIEINNFYTVTVYEKGAEVIRMLHTLLGEEGFRKGMDLY 400
                         410       420       430
                  ....*....|....*....|....*....|....
gi 1952201268 409 FERHDGQAVTCDDFVAAMSDASGIDLTQFKRWYS 442
Cdd:cd09600   401 FERHDGQAVTCEDFVAAMEDASGRDLSQFKRWYS 434
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
7-622 0e+00

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 566.58  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268   7 PQAQYLKDYQAPQFSIKHIDLRFELAPLKTSVQSTMTI--NRTDESNADLLLDGVDLTLISLMVDDKAYDdYTLEDEKLI 84
Cdd:COG0308     2 KRLTRLEAYRPPGYDVTHYDLDLDLDPATTRLSGTATItfTATEAPLDSLVLDLKGLEVTSVTVDGKPLD-FTRDGERLT 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  85 IH---NLP--ESFILKIENHIVPQTntSLEGLYLSG------GAYCTQCEAEGFRkiTYYL--DRPDVLASFDVTIIADK 151
Cdd:COG0308    81 ITlpkPLApgETFTLEIEYSGKPSN--GGEGLYRSGdppdgpPYLYTQCEPEGAR--RWFPcfDHPDDKATFTLTVTVPA 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 152 KYThLLSNGNQIESGNLDDGRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYttQSGrkVELALFVDKGNLSKTPHAMTSL 231
Cdd:COG0308   157 GWV-AVSNGNLVSETELGDGRTTWHWADTQPIPTYLFALAAGDYAVVEDTF--ASG--VPLRVYVRPGLADKAKEAFEST 231
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 232 KKSMQWDEERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVlaNQETATDKDYHTIESIVGHEYFHNWTGNRVTC 311
Cdd:COG0308   232 KRMLDFFEELFGVPYPFDKYDQVAVPDFNFGAMENQGLVTFGEKVL--ADETATDADYERRESVIAHELAHQWFGNLVTC 309
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 312 RDWFQLSLKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRM 391
Cdd:COG0308   310 ADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHPIRPDDYPEIENFFDGIVYEKGALVLHM 389
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 392 MHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLT-QFKRWYSQAGTPKLNVEQAYDEQNQTfTLSIEQFA 470
Cdd:COG0308   390 LRTLLGDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRDLSaFFDQWLYQAGLPTLEVEYEYDADGKV-TLTLRQTP 468
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 471 PDNQPnnalLHIPFAIELLDSEGQSLPLVIDnqpqdsvlnvTEKTQqfvfegIKQRPVAVLLEDFSapcivnqntsaADL 550
Cdd:COG0308   469 PRPHP----FHIPLEVGLLGGKLTARTVLLD----------GEQTE------LVAKPDPVLLLRLD-----------DEL 517
                         570       580       590       600       610       620       630
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 1952201268 551 LHIMRFARSDFSRWDAQQRLFtnemkaaiASGEAclsddilSALKLLVDNREGDLALIAELLKLPSYDTLAA 622
Cdd:COG0308   518 AFLLAHDSDPFNRWEALQALW--------RDGEA-------DYLDALRALADTDPAVRAEALALLGSDQLAL 574
DUF3458_C pfam17432
Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally ...
547-863 3.62e-122

Domain of unknown function (DUF3458_C) ARM repeats; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes.


Pssm-ID: 465424 [Multi-domain]  Cd Length: 324  Bit Score: 371.85  E-value: 3.62e-122
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 547 AADLLHIMRFARSDFSRWDAQQRLFTNEMKAAIA----SGEACLSDDILSALKLLVDNREGDLALIAELLKLPSYDTLAA 622
Cdd:pfam17432   1 DEDLAFLLAHDSDPFNRWEAGQTLALRLLLALVAalqaGEPLALDAAFIDAFRAVLADAALDPAFKAEALTLPSEAYLAE 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 623 EYAVIPVDDIIAVQNAFESQIANFLTESLVNCYNVLEDDG--STSATAVAVRALKQLCLYYLAKTNHSDVNSRIRESVHS 700
Cdd:pfam17432  81 QMDVVDPDAIHAAREALRRALAEALRDELLALYQALAATGpySPDAAAAGRRALRNLALSYLAAAGDPEAADLAAAQFES 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 701 -NNMTNALAALSAVVKANHSLCDTLLTEFDAKWRHDVLVMDKWFALQAMKDSATSISDIKALYDHPSFDFGNPNRVRALV 779
Cdd:pfam17432 161 aDNMTDRLAALAALVNSDLPEREEALADFYQRWKDDPLVMDKWFALQATSPRPDTLERVKALMQHPAFDLKNPNRVRALI 240
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 780 GSFSHFNITQFHRADGEGYQLLGDLLVKLNDINPQNASRMLTPFMSWKRYDENRSAAMKAQLQRLADLDGLSDDLFEKVE 859
Cdd:pfam17432 241 GAFAAANPVAFHAADGSGYRFLADQVLELDAINPQVAARLLTPLTRWRRYDPPRQALMRAALERIAATPGLSKDVFEIVS 320

                  ....
gi 1952201268 860 KALE 863
Cdd:pfam17432 321 KALA 324
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
23-428 7.85e-115

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 356.37  E-value: 7.85e-115
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  23 KHIDLRFEL--APLKTSVQSTMTInRTDESNADLLLDGVDLTLISLMVDDKAYD---DYTLEDEKLII---HNLPESFIL 94
Cdd:cd09595     1 YHYDLDLDVdfTTKTLNGTETLTV-DASQVGRELVLDLVGLTIHSVSVNGAAVDfgeREHYDGEKLTIpgpKPPGQTFTV 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  95 KIENHIVPQTNTSL----EGLYLSGGAYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADKKYtHLLSNGNQIESGNLDD 170
Cdd:cd09595    80 RISFEAKPSKNLLGwlweQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKD-LLASNGALVGEETGAN 158
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 171 GRHFVKWQDPFKKPSYLFALVAGDFDVLRDHYTTQsgRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFNLEYDLDI 250
Cdd:cd09595   159 GRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQ--PRVGLSVYSEPLQVDQAQYAFDATRAALAWFEDYFGGPYPLPK 236
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 251 YMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDkdYHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVFRDQE 330
Cdd:cd09595   237 YDLLAVPDFNSGAMENPGLITFRTTYLLRSKVTDTG--ARSIENVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYYENR 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 331 FSSDLG---SRALNRIDAVKVMRTHQFSEDAGPMAHPIRpeKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMAL 407
Cdd:cd09595   315 IMDATFgtsSRHLDQLSGSSDLNTEQLLEDSSPTSTPVR--SPADPDVAYDGVTYAKGALVLRMLEELVGEEAFDKGVQA 392
                         410       420
                  ....*....|....*....|.
gi 1952201268 408 YFERHDGQAVTCDDFVAAMSD 428
Cdd:cd09595   393 YFNRHKFKNATTDDFIDALEE 413
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
227-440 2.34e-66

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 220.62  E-value: 2.34e-66
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 227 AMTSLKKSMQWDEERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTG 306
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALPDFSAGAMENWGLITYRETLLLYDPGNSSTSDKQRVASVIAHELAHQWFG 81
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 307 NRVTCRDWFQLSLKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQFSEDAGPMAHPI--RPEKVIEMNNFYTVTVYDK 384
Cdd:pfam01433  82 NLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPItqNVNDPSEIDDIFDAIPYEK 161
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|....*...
gi 1952201268 385 GAEVIRMMHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASG-IDLTQF-KRW 440
Cdd:pfam01433 162 GASVLRMLETLLGEEVFQKGLRSYLKKFQYGNATTEDLWDALSEASGpLDVDSFmDTW 219
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
20-441 8.45e-55

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 195.11  E-value: 8.45e-55
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  20 FSIKHIDLRFELAPLKTSVQSTMTIN-RTDESNADLLLDGVDLTLISLMVDDKAYDDYTLEDEKLIIhNLP------ESF 92
Cdd:cd09603     1 YDVLHYDLDLDYDPATKSLSGTATITfRATQDLDSLQLDLVGLTVSSVTVDGVPAAFFTHDGDKLVI-TLPrplaagETF 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  93 ILKIENHIVPQTNTSLEGL-----YLSGGAYcTQCEAEGFRkiTYY--LDRPDVLASFDVTIIADKKYThLLSNGNQIES 165
Cdd:cd09603    80 TVTVRYSGKPRPAGYPPGDgggweEGDDGVW-TAGQPEGAS--TWFpcNDHPDDKATYDITVTVPAGLT-VVSNGRLVST 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 166 GNLDDGRHFVKWQDPFKKPSYLFALVAGDFDvlrdHYTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSMQWDEERFnLE 245
Cdd:cd09603   156 TTNGGGTTTWHWKMDYPIATYLVTLAVGRYA----VVEDGSGGGIPLRYYVPPGDAAKAKASFARTPEMLDFFEELF-GP 230
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 246 YDLDIYMIVAVDFFNmGAMENKGLNIFNSKCVLANqetatdkdyHTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTV 325
Cdd:cd09603   231 YPFEKYGQVVVPDLG-GGMEHQTATTYGNNFLNGD---------RGSERLIAHELAHQWFGDSVTCADWADIWLNEGFAT 300
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 326 FrdqefSSDLGSRALNRIDAvkvMRTHQFSEDAGPMAHPIRPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGM 405
Cdd:cd09603   301 Y-----AEWLWSEHKGGADA---YRAYLAGQRQDYLNADPGPGRPPDPDDLFDRDVYQKGALVLHMLRNLLGDEAFFAAL 372
                         410       420       430
                  ....*....|....*....|....*....|....*..
gi 1952201268 406 ALYFERHDGQAVTCDDFVAAMSDASGIDLTQ-FKRWY 441
Cdd:cd09603   373 RAYLARYAHGNVTTEDFIAAAEEVSGRDLTWfFDQWL 409
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
24-435 1.88e-52

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 189.71  E-value: 1.88e-52
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  24 HIDLRFELAPLKTSVQSTMTINRTDESN------ADLLLDGVDLTLISLMVDDKAYDDYTLEDEKLIIH---NLP--ESF 92
Cdd:cd09601     4 DLTLTPDLENFTFSGSVTITLEVLEPTDtivlhaKDLTITSASLTLKGGSGIIEVTVVTDEETEFLTITldeTLPpgENY 83
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  93 ILKIE--NHIvpqtNTSLEGLYLS-----GGA----YCTQCEAEGFRKItyY--LDRPDVLASFDVTIIADKKYTHLlSN 159
Cdd:cd09601    84 TLSIEftGKL----NDDLRGFYRSsytdeDGEtrylAATQFEPTDARRA--FpcFDEPAFKATFDITITHPKGYTAL-SN 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 160 GNQIESGNLDDGRHFVKwqdpFKK----PSYLFALVAGDFDVLrdhyTTQSGRKVELALFVDKGNLSKTPHAMTSLKKSM 235
Cdd:cd09601   157 MPPVESTELEDGWKTTT----FETtppmSTYLVAFVVGDFEYI----ESTTKSGVPVRVYARPGKIEQGDFALEVAPKIL 228
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 236 QWDEERFNLEYDL---DIymiVAVDFFNMGAMENKGLNIFNSKCVLANQETATDKDYHTIESIVGHEYFHNWTGNRVTCR 312
Cdd:cd09601   229 DFYEDYFGIPYPLpklDL---VAIPDFAAGAMENWGLITYRETALLYDPKTSSASDKQRVAEVIAHELAHQWFGNLVTMK 305
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 313 DWFQLSLKEGltvfrdqeFSSDLGSRALN------RIDAVKVMRTHQ--FSEDAGPMAHPIRP--EKVIEMNNFYTVTVY 382
Cdd:cd09601   306 WWDDLWLNEG--------FATYMEYLAVDklfpewNMWDQFVVDELQsaLELDSLASSHPIEVpvESPSEISEIFDAISY 377
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|...
gi 1952201268 383 DKGAEVIRMMHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLT 435
Cdd:cd09601   378 SKGASVLRMLENFLGEEVFRKGLRKYLKKHAYGNATTDDLWEALQEASGESKP 430
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
19-440 2.10e-44

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 166.54  E-value: 2.10e-44
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  19 QFSIKHIDLRFELAPLKTSVQSTMTIN-RTDESNADLLLDGVDLTLISLMVDDKAYDDYTLEDEKLIIHNLPesfiLKIE 97
Cdd:cd09602    12 LISVVSYDLDLDLTEGAETFRGTVTIRfTLREPGASLFLDFRGGEVKSVTLNGRPLDPSAFDGERITLPGLL----KAGE 87
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  98 NHIV-----PQTNTSlEGLY-----LSGGAY-CTQCEAEGFRKITYYLDRPDVLASFDVTIIADKKYThLLSNGNQIESG 166
Cdd:cd09602    88 NTVVveftaPYSSDG-EGLHrfvdpADGETYlYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPADWT-VISNGPETSTE 165
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 167 NLDDGRHfvkWQdpFKK----PSYLFALVAGDFDVLRDhyttqSGRKVELALFVDKgnlSKTPHAM------TSLKKSMQ 236
Cdd:cd09602   166 EAGGRKR---WR--FAEtpplSTYLFAFVAGPYHRVED-----EHDGIPLGLYCRE---SLAEYERdadeifEVTKQGLD 232
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 237 WDEERFNLEYDLDIYMIVAVDFFNMGAMENKGLNIFNSKCVLanQETATDKDYHTIESIVGHEYFHNWTGNRVTCRDWFQ 316
Cdd:cd09602   233 FYEDYFGIPYPFGKYDQVFVPEFNFGAMENPGAVTFRESYLF--REEPTRAQRLRRANTILHEMAHMWFGDLVTMKWWDD 310
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 317 LSLKEgltVFRDqeFSSDLGSRALNR-IDA-VKVMRTHQ---FSEDAGPMAHPIRPEkvIE-----MNNFYTVTvYDKGA 386
Cdd:cd09602   311 LWLNE---SFAD--FMAAKALAEATPfTDAwLTFLLRRKpwaYRADQLPTTHPIAQD--VPdleaaGSNFDGIT-YAKGA 382
                         410       420       430       440       450
                  ....*....|....*....|....*....|....*....|....*....|....*
gi 1952201268 387 EVIRMMHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASGIDLTQFKR-W 440
Cdd:cd09602   383 SVLKQLVALVGEEAFRAGLREYFKKHAYGNATLDDLIAALDEASGRDLSAWADaW 437
DUF3458 pfam11940
Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally ...
445-544 2.41e-33

Domain of unknown function (DUF3458) Ig-like fold; This presumed domain is functionally uncharacterized. This domain is found in bacteria, archaea and eukaryotes. The domain has an Ig-like fold. This domain is found associated with pfam01433.


Pssm-ID: 463405 [Multi-domain]  Cd Length: 95  Bit Score: 123.39  E-value: 2.41e-33
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 445 GTPKLNVEQAYDEQNQTFTLSIEQFAPD--NQPNNALLHIPFAIELLDSEGQSLPLvidnqpqDSVLNVTEKTQQFVFEG 522
Cdd:pfam11940   1 GTPRVTVSDSYDAAAGTYTLTLSQTTPPtpGQPEKQPLHIPIRIALLDPNGQELAL-------ERVLELTEAEQTFTFEG 73
                          90       100
                  ....*....|....*....|..
gi 1952201268 523 IKQRPVAVLLEDFSAPCIVNQN 544
Cdd:pfam11940  74 VAEKPVPSLLRGFSAPVKLEYD 95
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
24-187 1.79e-24

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 101.27  E-value: 1.79e-24
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  24 HIDLRFE--LAPLKTSVQSTMTINRTDESNaDLLLDGVDLTLISLMVDDKAYDDYTLED--------EKLIIH-----NL 88
Cdd:pfam17900   4 HYDLDLKidLKNFTFSGSVTITLQLNNATN-VIVLHASDLTIRSISLSDEVTSDGVPADftedqkdgEKLTIVlpetlNQ 82
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  89 PESFILKIEnhIVPQTNTSLEGLY-----LSGG---AYCTQCEAEGFRKITYYLDRPDVLASFDVTIIADKKYTHlLSNG 160
Cdd:pfam17900  83 TGPYTLEIE--YSGELNDSMTGFYrstytDNGEkkvLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTA-LSNM 159
                         170       180
                  ....*....|....*....|....*..
gi 1952201268 161 NQIESGNLDDGRHFVKWQDPFKKPSYL 187
Cdd:pfam17900 160 PVIASEPLENGWVITTFEQTPKMSTYL 186
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
20-457 1.26e-18

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 90.61  E-value: 1.26e-18
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  20 FSIKHIDLRFELAPLKTSVQSTMT--INRTDESNADLLLDGVDLTLISLMVDDKAYDdYTLEDEK------LIIhNLP-- 89
Cdd:TIGR02411  11 FRTSHTDLNLSVDFTKRKLSGSVTftLKSLTDNLNKLVLDTSYLDIQKVTINGLPAD-FAIGERKeplgspLTI-SLPia 88
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  90 ----ESFILKIENHIVPQTnTSLEGL---YLSGGAY---CTQCEAEGFRKITYYLDRPDVLASFDVTIiaDKKYTHLLSn 159
Cdd:TIGR02411  89 tsknDEFVLNISFSTTPKC-TALQWLnpeQTSGKKHpylFSQCQAIHARSLFPCQDTPSVKSTYTAEV--ESPLPVLMS- 164
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 160 GNQIESGNLDDGRHFVKWQDPFkkPSYLFALVAGDFDvlrdhyTTQSGRKVelALFVDKGNLSKTPHAMTSLKKSMQWDE 239
Cdd:TIGR02411 165 GIRDGETSNDPGKYLFKQKVPI--PAYLIAIASGDLA------SAPIGPRS--TVYSEPEQLEKCQYEFENDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 240 ERFNLEYDLDIY-MIVAVDFFNMGAMENKGLNiFNSKCVLANQETATDkdyhtiesIVGHEYFHNWTGNRVTCRDWFQLS 318
Cdd:TIGR02411 235 EDLIFPYEWGQYdLLVLPPSFPYGGMENPNLT-FATPTLIAGDRSNVD--------VIAHELAHSWSGNLVTNCSWEHFW 305
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 319 LKEGLTVF------------RDQEFSSDLGSRALNriDAVKVM-RTHQFS------EDAGPmahpirpekviemNNFYTV 379
Cdd:TIGR02411 306 LNEGWTVYlerriigrlygeKTRHFSALIGWGDLQ--ESVKTLgETPEFTklvvdlKDNDP-------------DDAFSS 370
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 380 TVYDKGAEVIRMMHTLLG-EEKFQQGMALYFERHDGQAVTCDDFVAAMSD-------ASGIDLTQFKRWYSQAGTPklNV 451
Cdd:TIGR02411 371 VPYEKGFNFLFYLEQLLGgPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEyfkdkkkVDKLDAVDWETWLYSPGMP--PV 448

                  ....*.
gi 1952201268 452 EQAYDE 457
Cdd:TIGR02411 449 KPNFDT 454
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
131-441 8.60e-18

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 86.95  E-value: 8.60e-18
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 131 TYYLDrpdvLASFDVTIIADKKYThLLSNGNQIESGNLDDGR---HFVKWQ--DpfkkpsylFALVAGDfdvlrdHYTTQ 205
Cdd:cd09604   155 FFYSD----FGDYDVTITVPKNYV-VAATGELQNPEEVLDGTktwHFKAENvrD--------FAWAASP------DFVVD 215
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 206 SGRK--VELALFVDKGNLSKTPHAMTSLKKSMQWDEERFnLEYDLDIYMIVAVDFFNmGAMENKGLnIFNSkcvlanqeT 283
Cdd:cd09604   216 AATVdgVTVNVYYLPENAEAAERALEYAKDALEFFSEKF-GPYPYPELDVVQGPFGG-GGMEYPGL-VFIG--------S 284
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 284 ATDKDYHTIESIVGHEYFHNW----TGNrvtcrD-----WfqlsLKEGLTVFRDQEFSSDLGSRALNRIDAVKVMRTHQF 354
Cdd:cd09604   285 RLYDPKRSLEGVVVHEIAHQWfygiVGN-----DerrepW----LDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYA 355
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 355 SEDAGPMAHPIrpekvIEMNNF--YTVTVYDKGAEVIRMMHTLLGEEKFQQGMALYFERHDGQAVTCDDFVAAMSDASGI 432
Cdd:cd09604   356 RGPGGPINLPL-----DTFPDGsyYSNAVYSKGALFLEELREELGDEAFDKALREYYRRYKFKHPTPEDFFRTAEEVSGK 430
                         330
                  ....*....|
gi 1952201268 433 DLTQF-KRWY 441
Cdd:cd09604   431 DLDWFfRGWL 440
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
19-424 1.47e-16

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 83.28  E-value: 1.47e-16
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  19 QFSIKHIDLRFELAPLKTSVQ--STMTINRTDESNADLLLDGVDLTLISLMVDDKAYDDYTLED------EKLIIH---- 86
Cdd:cd09599    10 EVRTTHLDLDLTVDFDKKTISgsATLTLEVLQDGADELVLDTRDLDISSVTVNGGKELKFELGPrdpvlgSALTITlpsp 89
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268  87 -NLPESFILKIENHIVP-----------QTntsleglylSGGAY---CTQCEAEGFRKITYYLDRPDVLASFDVTIIADK 151
Cdd:cd09599    90 lAKGDTFKVKIEYSTTPqatalqwltpeQT---------AGKKHpylFTQCQAIHARSLFPCQDTPSVKSTYSATVTVPK 160
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 152 KYTHLLSNGNQIESGNLDDGRHfvKWQDPFKKPSYLFALVAGDFDvlrdhyttqsGRKV--------------------- 210
Cdd:cd09599   161 GLTALMSALRTGEKEEAGTGTY--TFEQPVPIPSYLIAIAVGDLE----------SREIgprsgvwaepsvvdaaaeefa 228
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 211 ELALFVDKGnlsktphamtslkksmqwdeERFNLEYDLDIY-MIVAVDFFNMGAMENKGLnIFNSKCVLanqetATDKdy 289
Cdd:cd09599   229 DTEKFLKAA--------------------EKLYGPYVWGRYdLLVLPPSFPYGGMENPCL-TFATPTLI-----AGDR-- 280
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 1952201268 290 hTIESIVGHEYFHNWTGNRVTCRDWFQLSLKEGLTVF--R----------DQEFSSDLGSRALnrIDAVKvmrthQFSED 357
Cdd:cd09599   281 -SLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYleRrilerlygeeYRQFEAILGWKDL--QESIK-----EFGED 352
                         410       420       430       440       450       460
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 1952201268 358 AGPMAHPIrPEKVIEMNNFYTVTVYDKGAEVIRMMHTLLGEEKFQQGMALYFERHDGQAVTCDDFVA 424
Cdd:cd09599   353 PPYTLLVP-DLKGVDPDDAFSSVPYEKGFQFLYYLEQLGGREVFDPFLRAYFKKFAFQSIDTEDFKD 418
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH